Use of the Insulin Pump in Cystic Fibrosis Patients With Impaired Glucose Tolerance or CFRD and in Type 1 Diabetes Patients.

• Status: Withdrawn
• Trial end date: 2006-02-02
• Target enrollment: 0
• Participant gender: All

Summary

We hypothesize use of the insulin pump will improve body weight, lean body mass, whole body protein turnover, hepatic glucose production (HGP), and blood sugar control in CF patients with impaired glucose tolerance or patients with CF related diabetes (CFRD). We further hypothesize that HGP is also elevated in children/adolescents with type 1 diabetes and that the insulin pump will result in decreased HGP.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Texas Southwestern Medical Center
• Treatments: Insulin; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Cystic fibrosis patients aged 12-32 years

• Impaired glucose tolerance or CFRD defined as fasting blood glucose (FBG) and post-prandial blood glucose (pp) equal to: FBG <126 and pp 151-200, or FBG <126 and pp >200, or FBG >126 and pp >200.

• Type 1 diabetes control patients aged 12-32 years.

Exclusion Criteria:

• Colonization with Burkholderia cepacia

• currently on corticosteroid medication

• pregnant

• medically unstable

• Unable to understand the insulin pump directions